» Articles » PMID: 34158591

The Pan-cancer Landscape of Crosstalk Between Epithelial-mesenchymal Transition and Immune Evasion Relevant to Prognosis and Immunotherapy Response

Overview
Publisher Springer Nature
Specialty Oncology
Date 2021 Jun 23
PMID 34158591
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

An emerging body of evidence has recently recognized the coexistence of epithelial-mesenchymal transition (EMT) and immune response. However, a systems-level view and survey of the interplay between EMT and immune escape program, and their impact on tumor behavior and clinical outcome across various types of cancer is lacking. Here, we performed comprehensive multi-omics analyses to characterize the landscape of crosstalk between EMT and immune evasion and their clinical relevance across 17 types of solid cancer. Our study showed the presence of complex and dynamic immunomodulatory crosstalk between EMT and immune evasion shared by pan-cancer, and the crosstalk was significantly associated with cancer prognosis and immunotherapy response. Integrative quantitative analyses of genomics and immunogenomics revealed that cellular composition of immune infiltrates, non-synonymous mutation burden, chromosomal instability and oncogenic gene alterations are associated with the balance between EMT and immune evasion. Finally, we proposed a scoring model termed EMT-CYT Index (ECI) to quantify the EMT-immunity axis, which was a superior predictor of prognosis and immunotherapy response across different malignancies. By providing a systematic overview of crosstalk between EMT and immune evasion, our study highlights the potential of pan-cancer EMT-immunity crosstalk as a paradigm for dissecting molecular mechanisms underlying cancer progression and guiding more effective and generalized immunotherapy strategies.

Citing Articles

Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.

Tufail M, Jiang C, Li N Mil Med Res. 2025; 12(1):7.

PMID: 39934876 PMC: 11812268. DOI: 10.1186/s40779-025-00595-2.


The complexity of immune evasion mechanisms throughout the metastatic cascade.

Haynes N, Chadwick T, Parker B Nat Immunol. 2024; 25(10):1793-1808.

PMID: 39285252 DOI: 10.1038/s41590-024-01960-4.


Construction of a cuproptosis‑related lncRNA signature to predict biochemical recurrence of prostate cancer.

Yu Z, Deng H, Chao H, Song Z, Zeng T Oncol Lett. 2024; 28(5):526.

PMID: 39268161 PMC: 11391508. DOI: 10.3892/ol.2024.14659.


Molecular characterization of the salivary adenoid cystic carcinoma immune landscape by anatomic subsites.

Tasoulas J, Schrank T, Bharambe H, Mehta J, Johnson S, Divaris K Sci Rep. 2024; 14(1):15821.

PMID: 38982149 PMC: 11233590. DOI: 10.1038/s41598-024-66709-3.


Elevated SLC3A2 associated with poor prognosis and enhanced malignancy in gliomas.

Xu Y, Weng W, Weng Y, Chen D, Zheng Z, Fan Z Sci Rep. 2024; 14(1):15758.

PMID: 38977800 PMC: 11231275. DOI: 10.1038/s41598-024-66484-1.


References
1.
Shibue T, Weinberg R . EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017; 14(10):611-629. PMC: 5720366. DOI: 10.1038/nrclinonc.2017.44. View

2.
Redfern A, Spalding L, Thompson E . The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome. Clin Exp Metastasis. 2018; 35(4):285-308. DOI: 10.1007/s10585-018-9906-x. View

3.
Sarrio D, Rodriguez-Pinilla S, Hardisson D, Cano A, Moreno-Bueno G, Palacios J . Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008; 68(4):989-97. DOI: 10.1158/0008-5472.CAN-07-2017. View

4.
Fischer K, Durrans A, Lee S, Sheng J, Li F, Wong S . Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015; 527(7579):472-6. PMC: 4662610. DOI: 10.1038/nature15748. View

5.
Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View